CAR-T Meeting 2022 | Managing CRS after CAR-T therapy
Pere Barba
• 10 Feb 2022
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, talks on the management of cytokine release syndrome (CRS) after chimeric antigen receptor T-cell (CAR-T) therapy. This includes starting tocilizumab early and adding other second and third-line therapies for patients who do not respond to tocilizumab. Moving forward, it would be interesting to design improved CAR-T constructs and find biomarkers to help identify patients at a high risk of CRS. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
